Co-Diagnostics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
CODX$0.32+24.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $14,916,878 | $22,973,803 |
| Marketable investment securities | 43,631,510 | 58,289,066 |
| Accounts receivable, net | 303,926 | 3,453,723 |
| Inventory, net | 1,664,725 | 5,310,473 |
| Income taxes receivable | 26,955 | 1,870,419 |
| Prepaid expenses and other current assets | 1,597,114 | 761,187 |
| Note receivable | - | 75,000 |
| Total current assets | 62,141,108 | 92,733,671 |
| Property and equipment, net | 3,035,729 | 2,539,483 |
| Operating lease right-of-use asset | 2,966,774 | 372,115 |
| Intangible assets, net | 26,403,667 | 26,768,333 |
| Investment in joint venture | 773,382 | 672,679 |
| Total assets | $95,320,660 | $123,086,281 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $1,482,109 | $952,296 |
| Accrued expenses | 2,172,959 | 934,447 |
| Operating lease liability, current | 838,387 | 297,209 |
| Contingent consideration liabilities, current | 891,666 | 1,689,471 |
| Deferred revenue | 362,449 | - |
| Total current liabilities | 5,747,570 | 3,873,423 |
| Long-term liabilities | ||
| Income taxes payable | 659,186 | 1,181,284 |
| Deferred tax liability | - | 2,417,987 |
| Operating lease liability | 2,152,180 | 50,708 |
| Contingent consideration liabilities | 748,109 | 1,042,885 |
| Total long-term liabilities | 3,559,475 | 4,692,864 |
| Total liabilities | 9,307,045 | 8,566,287 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity | ||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | - | - |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022 | 36,108 | 34,754 |
| Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively | (15,575,795) | (14,211,866) |
| Additional paid-in capital | 96,808,436 | 88,472,935 |
| Accumulated other comprehensive income | 146,700 | 293,140 |
| Accumulated earnings | 4,598,166 | 39,931,031 |
| Total stockholders’ equity | 86,013,615 | 114,519,994 |
| Total liabilities and stockholders’ equity | $95,320,660 | $123,086,281 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.